Replies to post #198260 on NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

Guys, don’t you get why they keep telling you “>90% received DCVax?”

Don’t you see it?

"Think for yourselves and let others enjoy the privilege to do so, too."

-Voltaire

[Evaluate]

you wrote:

Guys, don’t you get why they keep telling you “>90% received DCVax?”
Don’t you see it?

Nope, I "do not see it". See what? Not sure what you see?

I do not believe they have ever stated: “>90% received DCVax?”
Instead, I believe they always stated about or almost 90%.

In the journal (https://www.nwbio.com/wp-content/uploads/2018/08/J-Transl-Med.pdf):

Nevertheless, since the vast majority (86.4%) of the ITT population received the experimental DC treatment at some point during the trial because of the cross-over study design, analysis of the interim data may provide early insight into the impact of DCVax-L on overall survival.

In the PR (https://www.nwbio.com/nwbio-announces-scientific-publication-interim-survival-data-phase-3-trial-dcvax-l-glioblastoma-brain-cancer/):

Due to the crossover design, nearly 90% of the total 331 patients in the trial have received DCVax-L treatment.

So, assuming that the 86.4% is correct, that would be 286 patients.
Now, if the current slide indicates "over 90%" (for the first time, I believe), then this would be at least 298 patients.
Thus, an increase of at least 12 patients that have crossed between the Spring 2017 refresh, and the currently reflected data ... supposedly current through November 2018.

For the folks on this MB that are keeping track of such patient counts .... does this seem reasonable to have expected that many additional patients to cross over?

And Pyrr ... what is it that you "see"?